GLORIA CHENG: Open Payments
NPI 1548662109 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,228 in 10 payments from 8 companies in 2025. Trend: 2023 $1,180 · 2024 $670 · 2025 $1,228
Food & beverage: $1,228
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 2 | $272 |
| Lilly USA, LLC | 2 | $245 |
| Organon LLC | 1 | $168 |
| LEO Pharma Inc. | 1 | $137 |
| Teva Pharmaceuticals USA, Inc. | 1 | $132 |
| Madrigal Pharmaceuticals | 1 | $130 |
| Gilead Sciences, Inc. | 1 | $118 |
| Dexcom, Inc. | 1 | $26 |
Products named: NEMLUVIO, VTAMA, ADBRY, REZDIFFRA, ZEPBOUND, OMVOH, Yeztugo, Dexcom G6 Transmitter.
Industry payments across CA — which companies pay providers there.
